SCHEMBL1198741

SCHEMBL1198741

CCN(Cc1ccccc1)C(CCP(=O)(O)O)CCP(=O)(O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.43
S1PR4 O95977 1/20 0.43
S1PR1 P21453 1/20 0.43
S1PR3 Q99500 1/20 0.43
LMNA P02545 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ANPEP P15144 3/20 0.41
ERAP1 Q9NZ08 2/20 0.41
ERAP2 Q6P179 1/20 0.41
OPRD1 P41143 1/20 0.40
ACP3 P15309 1/20 0.40
BCHE P06276 1/20 0.39
LAP3 P28838 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1197672 0.91 S1PR2 (0.48) S1PR2S1PR4S1PR1S1PR3ALDH1A1
Morpholine SCHEMBL1198041 0.87 S1PR2 (0.35) S1PR2S1PR4S1PR1S1PR3LMNA
SCHEMBL1198018 0.81 S1PR2 (0.46) S1PR2S1PR4S1PR1S1PR3ALDH1A1
Morpholine SCHEMBL1198843 0.77 S1PR2 (0.38) S1PR2S1PR4S1PR1S1PR3ALDH1A1
Ammonia Solution, Strong SCHEMBL1197667 0.75 ALDH1A1 (0.39) LMNAALDH1A1MEN1KMT2AANPEP
SCHEMBL12126189 0.75 TSHR (0.48) LMNAALDH1A1KMT2AOPRD1BCHE
SCHEMBL8069172 0.74 OPRD1 (0.50) LMNAKMT2AOPRD1BCHENPC1
SCHEMBL11540558 0.73 ANPEP (0.48) ALDH1A1MEN1KMT2AANPEPERAP1
SCHEMBL3272617 0.72 S1PR2 (0.44) S1PR2S1PR4S1PR1S1PR3ALDH1A1
SCHEMBL19435319 0.72 TSHR (0.46) LMNAALDH1A1MEN1KMT2AOPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034714-A1 METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND EKIMOTO HISAO 2011-02-10 US disclosed
EP-2177525-A1 METAL COMPLEX COMPOUND, CANCER THERAPEUTIC COMPOSITION COMPRISING THE METAL COMPLEX COMPOUND AS ACTIVE INGREDIENT, AND INTERMEDIATE FOR PRODUCTION OF THE METAL COMPLEX COMPOUND TMRC Co., Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034714-A1 METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND NR3C2, NR3C1, MC5R S1PR2 3219/4885S1PR4 3431/4885S1PR1 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.